In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Lights, Camera, Compassion: Natalie Portman promotes Uncaged Innovations’ cruelty-free leather alternative
In New York, A-list star Natalie Portman has signed on to promote leather alternatives developed and manufactured by Uncaged Innovations. Portman, a long-standing advocate...
Time for snackies! Dogs love BeneMeat’s cultivated meat treats
In Prague, BeneMeat, a cultivated meat company targeting pet food, revealed that 90% of dog owners participating in a 25-country “Try & Share” lab-grown...
Locus Fermentation Solutions raises $20 million
In Ohio, Locus Fermentation Solutions has closed an oversubscribed, $20-million investment in a convertible note round at an equity valuation of $100 million. The...